By Kevin Hylton | LexisNexis Practical Guidance In-house counsel are on the alert in 2023 for class action lawsuits that could be filed at any time related to how their company safeguards the data privacy...
Online retailers had largely escaped state sales and use taxes before the U.S. Supreme Court decided South Dakota v. Wayfair, Inc. in 2018. Wayfair overruled the previous physical presence test which required...
Joint ventures are a common business arrangement for real estate investment. In order to create a successful partnership, though, it is crucial to find the right partner. Read this article for guidance...
This checklist covers FDA medical device facility registration and medical device listing requirements. Failure to register and list with the FDA may render a device misbranded, adulterated, or both. In...
Cash was not king when it came to merger consideration in the first quarter of 2023. Reflective perhaps of broader economic uncertainty regarding the post-closing success of acquisitions over the near...
This practice note outlines key considerations for attorneys who negotiate and draft research and development agreements (RDAs) for clients in the life sciences industry. RDAs typically involve two or more collaborators combining expertise to undertake mutually beneficial research and development activities.
Read now »
Related Content
Practical Guidance Updates Featuring the latest updates from your Practical Guidance account.
PRACTICAL GUIDANCE CUSTOMER EMAIL EDITION ON THE WEB
Experience results today with practical guidance, legal research, and data-driven insights—all in one place.Experience Lexis+